PepDiana
Back to Evidence
Primary experimental recordPositive observation

PMC12016742::ACT015719

GI

Evidence text

Paper-level observation

CD4+ T cell (P = 0.0002) (Figure 6j) and Caspase‐3 (P < 0.0001) (Figure 6l) levels induced by this combination immunotherapy were significantly higher than the ones quantified in the tumor of animals treated only with the multivalent conjugate.
textConfidence: medium

Assay observation

Activity
Immunomodulatory
Subtype
Antibacterial
Measure
percent_inhibition
Comparator
=
Raw observation
P = 0.0002 vs StCl-GI_GII
Normalized measurement
=0.0002
Value minimum
Not reported by source
Value maximum
Not reported by source
Target
Homo sapiens
Assay method
Not reported by source
Sequence
EGSRNQDWL
Standardization
ready simple

Source publication

Off‐The‐Shelf Multivalent Nanoconjugate Cancer Vaccine Rescues Host Immune Response against Melanoma

Advanced Materials · 2025

DOI 10.1002/adma.202417348 PMC12016742
Parent mention

Related peptide identities

PEPDIA-PLP-000563

Release PepDiana-V1-20260620. The stable record URL can be cited directly in supplementary material and downstream analyses.